Cell and Gene Therapy Market Size, Share, Trends, Growth Outlook

Cell and Gene Therapy Market is estimated to increase at a growth rate of 20.8% CAGR over the forecast period from 2024 to 2030.

The global Cell and Gene Therapy Market Study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Type (Cell Therapy, Gene Therapy), By Gene Type, Gene silencing, Cell replacement, Gene augmentation, Others), By Cell Type (T-Cells, Stem Cells, Other), By Application (Oncology, Dermatology, Musculoskeletal, Genetic Disorders, Others).

An Introduction to Cell and Gene Therapy Market in 2024

The Cell and Gene Therapy Market encompasses innovative therapeutic approaches that harness the potential of cellular and genetic technologies to treat various diseases and conditions. These therapies involve modifying or manipulating cells and genetic material to correct genetic disorders, enhance immune responses, and regenerate damaged tissues. In 2024, this market showcases breakthroughs in CAR-T cell therapies, gene editing techniques, stem cell therapies, and personalized medicine approaches, paving the way for revolutionary treatments and potential cures across a wide spectrum of diseases.

Cell and Gene Therapy Market Competitive Landscape

The global Cell and Gene Therapy Industry is highly competitive with a large number of companies focusing on niche market segments. Amidst intense competitive conditions, Cell and Gene Therapy Companies are investing in new product launches and strengthening distribution channels. Key companies operating in the Cell and Gene Therapy Industry include- Alnylam Pharmaceuticals Inc, Amgen Inc, Biogen Inc, Bluebird bio Inc, Bristol Myers Squibb Co., Castle Creek Biosciences Inc, CORESTEM Inc, Cytori Therapeutics Inc, Dendreon Pharmaceuticals LLC, Ferring BV, Gilead Sciences Inc, Helixmith Co. Ltd, Human Stem Cells Institute, JCR Pharmaceticals Co. Ltd, Kolon TissueGene Inc, Novartis AG, Orchard Therapeutics Plc, Pfizer Inc, Sibiono GeneTech Co. Ltd, Vericel Corp.

Cell and Gene Therapy Market Trend: Rapid Advancements in Technology and Research

A prominent trend in the Cell and Gene Therapy market is the rapid advancements in technology and research, driving innovation in the development and commercialization of novel therapies. Breakthroughs in gene editing technologies such as CRISPR-Cas9, advancements in cell manufacturing processes, and improved understanding of cellular biology have paved the way for the development of more precise, effective, and scalable cell and gene therapies. These technological advancements enable the engineering of cells to target specific diseases at the genetic level, leading to the development of personalized and potentially curative treatments for a wide range of medical conditions.

Cell and Gene Therapy Market Driver: Increasing Investment and Funding

The primary driver for the Cell and Gene Therapy market is the increasing investment and funding from both public and private sectors. Governments, pharmaceutical companies, biotechnology firms, and venture capitalists are allocating significant resources to support research and development activities in cell and gene therapy. The growing recognition of the therapeutic potential of cell and gene therapies, coupled with promising clinical trial results and regulatory approvals, has attracted substantial investment across the industry. Additionally, initiatives such as public-private partnerships, grant programs, and tax incentives further stimulate investment in the field, driving innovation and accelerating the translation of scientific discoveries into commercial products.

Cell and Gene Therapy Market Opportunity: Expansion of Therapeutic Applications

An opportunity for market growth in the Cell and Gene Therapy segment lies in the expansion of therapeutic applications beyond rare genetic disorders to more prevalent diseases, such as cancer, cardiovascular diseases, and autoimmune disorders. While initial focus has been on rare monogenic diseases, advancements in technology, manufacturing capabilities, and understanding of disease mechanisms present opportunities to develop cell and gene therapies for a broader range of indications. By leveraging the versatility and adaptability of cell and gene therapy platforms, there is potential to address unmet medical needs in larger patient populations, providing new treatment options for diseases with significant morbidity and mortality. Expanding therapeutic applications can drive market growth, increase patient access to innovative therapies, and diversify revenue streams for companies operating in the Cell and Gene Therapy market.

Market Share Analysis: Gene Therapy for Oncology is the fastest growing segment in the Cell and Gene Therapy industry

Among the options provided, gene therapy for oncology emerges as the fastest-growing segment in the field of cell and gene therapy. Gene therapy for oncology involves the use of genetically engineered vectors to deliver therapeutic genes into cancer cells, aiming to inhibit tumor growth, induce cell death, or enhance the immune system's ability to target and destroy cancer cells. With recent advancements in molecular biology and genetic engineering techniques, gene therapy has gained significant attention as a promising approach for treating various types of cancer. Clinical trials and research studies exploring gene therapy interventions for oncological conditions have shown promising results, leading to increased investment and interest from pharmaceutical companies, biotechnology firms, and research institutions. As a result, the gene therapy segment for oncology applications is anticipated to experience rapid growth, driven by ongoing research efforts, regulatory approvals, and the rising demand for innovative cancer treatments.

Cell and Gene Therapy Market Segmentation

By Type
Cell Therapy
Gene Therapy
By Gene Type
Gene silencing
Cell replacement
Gene augmentation
Others
By Cell Type
T-Cells
Stem Cells
Other
By Application
Oncology
Dermatology
Musculoskeletal
Genetic Disorders
Others
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

Cell and Gene Therapy Companies

Alnylam Pharmaceuticals Inc
Amgen Inc
Biogen Inc
Bluebird bio Inc
Bristol Myers Squibb Co.
Castle Creek Biosciences Inc
CORESTEM Inc
Cytori Therapeutics Inc
Dendreon Pharmaceuticals LLC
Ferring BV
Gilead Sciences Inc
Helixmith Co. Ltd
Human Stem Cells Institute
JCR Pharmaceticals Co. Ltd
Kolon TissueGene Inc
Novartis AG
Orchard Therapeutics Plc
Pfizer Inc
Sibiono GeneTech Co. Ltd
Vericel Corp
* List not Exhaustive

Reasons to Buy the Cell and Gene Therapy Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Cell and Gene Therapy Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Cell and Gene Therapy Industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

1 Introduction to 2024 Cell and Gene Therapy Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Cell and Gene Therapy Market Size Outlook, $ Million, 2021 to 2030
3.2 Cell and Gene Therapy Market Outlook by Type, $ Million, 2021 to 2030
3.3 Cell and Gene Therapy Market Outlook by Product, $ Million, 2021 to 2030
3.4 Cell and Gene Therapy Market Outlook by Application, $ Million, 2021 to 2030
3.5 Cell and Gene Therapy Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Cell and Gene Therapy Industry
4.2 Key Market Trends in Cell and Gene Therapy Industry
4.3 Potential Opportunities in Cell and Gene Therapy Industry
4.4 Key Challenges in Cell and Gene Therapy Industry

5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Cell and Gene Therapy Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Cell and Gene Therapy Market Outlook by Segments
7.1 Cell and Gene Therapy Market Outlook by Segments, $ Million, 2021- 2030
By Type
Cell Therapy
Gene Therapy
By Gene Type
Gene silencing
Cell replacement
Gene augmentation
Others
By Cell Type
T-Cells
Stem Cells
Other
By Application
Oncology
Dermatology
Musculoskeletal
Genetic Disorders
Others
8 North America Cell and Gene Therapy Market Analysis and Outlook To 2030
8.1 Introduction to North America Cell and Gene Therapy Markets in 2024
8.2 North America Cell and Gene Therapy Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Cell and Gene Therapy Market size Outlook by Segments, 2021-2030
By Type
Cell Therapy
Gene Therapy
By Gene Type
Gene silencing
Cell replacement
Gene augmentation
Others
By Cell Type
T-Cells
Stem Cells
Other
By Application
Oncology
Dermatology
Musculoskeletal
Genetic Disorders
Others
9 Europe Cell and Gene Therapy Market Analysis and Outlook To 2030
9.1 Introduction to Europe Cell and Gene Therapy Markets in 2024
9.2 Europe Cell and Gene Therapy Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Cell and Gene Therapy Market Size Outlook by Segments, 2021-2030
By Type
Cell Therapy
Gene Therapy
By Gene Type
Gene silencing
Cell replacement
Gene augmentation
Others
By Cell Type
T-Cells
Stem Cells
Other
By Application
Oncology
Dermatology
Musculoskeletal
Genetic Disorders
Others
10 Asia Pacific Cell and Gene Therapy Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Cell and Gene Therapy Markets in 2024
10.2 Asia Pacific Cell and Gene Therapy Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Cell and Gene Therapy Market size Outlook by Segments, 2021-2030
By Type
Cell Therapy
Gene Therapy
By Gene Type
Gene silencing
Cell replacement
Gene augmentation
Others
By Cell Type
T-Cells
Stem Cells
Other
By Application
Oncology
Dermatology
Musculoskeletal
Genetic Disorders
Others
11 South America Cell and Gene Therapy Market Analysis and Outlook To 2030
11.1 Introduction to South America Cell and Gene Therapy Markets in 2024
11.2 South America Cell and Gene Therapy Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Cell and Gene Therapy Market size Outlook by Segments, 2021-2030
By Type
Cell Therapy
Gene Therapy
By Gene Type
Gene silencing
Cell replacement
Gene augmentation
Others
By Cell Type
T-Cells
Stem Cells
Other
By Application
Oncology
Dermatology
Musculoskeletal
Genetic Disorders
Others
12 Middle East and Africa Cell and Gene Therapy Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Cell and Gene Therapy Markets in 2024
12.2 Middle East and Africa Cell and Gene Therapy Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Cell and Gene Therapy Market size Outlook by Segments, 2021-2030
By Type
Cell Therapy
Gene Therapy
By Gene Type
Gene silencing
Cell replacement
Gene augmentation
Others
By Cell Type
T-Cells
Stem Cells
Other
By Application
Oncology
Dermatology
Musculoskeletal
Genetic Disorders
Others
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Alnylam Pharmaceuticals Inc
Amgen Inc
Biogen Inc
Bluebird bio Inc
Bristol Myers Squibb Co.
Castle Creek Biosciences Inc
CORESTEM Inc
Cytori Therapeutics Inc
Dendreon Pharmaceuticals LLC
Ferring BV
Gilead Sciences Inc
Helixmith Co. Ltd
Human Stem Cells Institute
JCR Pharmaceticals Co. Ltd
Kolon TissueGene Inc
Novartis AG
Orchard Therapeutics Plc
Pfizer Inc
Sibiono GeneTech Co. Ltd
Vericel Corp
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Type
Cell Therapy
Gene Therapy
By Gene Type
Gene silencing
Cell replacement
Gene augmentation
Others
By Cell Type
T-Cells
Stem Cells
Other
By Application
Oncology
Dermatology
Musculoskeletal
Genetic Disorders
Others